Structure (C5b0f981 45c3 4e15 B712 984b4a4f6a57 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6406
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 02)
Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 03)
This is a graph illustrating the proportion of patients experiencing a relapse over time based on their treatment with either placebo or duloxetine. The x-axis shows the time elapsed in days from randomization to relapse, and the y-axis shows the proportion of patients experiencing relapse. The graph utilizes the Kaplan-Meier estimator method.*
Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 04)
This appears to be a table showing the percentage of patients who improved with different dosages of duloxetine and placebo, along with the percent improvement in pain from baseline. The text is not readable in a coherent manner, as it contains peculiar characters and symbols.*
Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 05)
The text provides data on the percentage improvement in pain from baseline for patients on Duloxetine 60 mg BID and QD compared to a placebo. However, the actual percentage values are missing, so no meaningful interpretation of the data can be made.*
Fig 5 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 06)
This appears to be a graph showing the percentage of patients who have improved based on varying levels of pain improvement in response to Duloxetine (a medication). The graph shows improvement percentages at different pain reduction levels ranging from 0% to 100%. The graph seems to show that patients who took Duloxetine showed greater improvement in pain than those who took a placebo.*
Fig 6 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 07)
The text represents a chart showing the percentage of patients who improved with different doses of Duloxetine and placebo, as well as the percent improvement in pain from baseline. There are no readable English characters for the scale on the X-axis of the chart.*
Figure 8 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 08)
This is a graph that displays the percentage of patients who reported improvements in pain levels after taking either a placebo or a daily dose of Duloxetine at either 60 or 120 mg. The percentage of improvement ranges from 0 to 100 percent, with increments of 10. The efficacy of Duloxetine can be determined based on the percentage of improvement reported by patients.*
Figure 9 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 09)
This is a chart showing the Percentage of Patients Improved with Duloxetine 60mg compared to Placebo in terms of pain (Percent Improvement in Pain from Baseline). There are percentages ranging from 0 to 100 on the vertical axis and numbered values on the horizontal axis.*
Figure 10 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 10)
This is a summary of the percentage of patients improved with duloxetine and placebo, where duloxetine showed an 80% improvement in comparison to placebo. Additionally, it includes a graph indicating the percentage improvement in pain from baseline for various percentages ranging from 10% to 90%.*
Label Image (Lbl500906406)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
